91 related articles for article (PubMed ID: 2576360)
21. Pharmacokinetics of the H1-receptor antagonist ebastine and its active metabolite carebastine in healthy subjects.
Yamaguchi T; Hashizume T; Matsuda M; Sakashita M; Fujii T; Sekine Y; Nakashima M; Uematsu T
Arzneimittelforschung; 1994 Jan; 44(1):59-64. PubMed ID: 7907873
[TBL] [Abstract][Full Text] [Related]
22. The effects of age and liver disease on the disposition and elimination of diazepam in adult man.
Klotz U; Avant GR; Hoyumpa A; Schenker S; Wilkinson GR
J Clin Invest; 1975 Feb; 55(2):347-59. PubMed ID: 1127104
[TBL] [Abstract][Full Text] [Related]
23. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys.
Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y
Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of famotidine after intravenous administration in liver disease.
Ohnishi K
Am J Gastroenterol; 1991 Jan; 86(1):41-5. PubMed ID: 1986553
[TBL] [Abstract][Full Text] [Related]
25. Oral and intravenous pharmacokinetics of cimetidine in liver cirrhosis.
Okolicsanyi L; Venuti M; Orlando R; Lirussi F; Nassuato G; Benvenuti C
Int J Clin Pharmacol Ther Toxicol; 1982 Oct; 20(10):482-7. PubMed ID: 7141756
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of brodimoprim.
Weidekamm E
J Chemother; 1993 Dec; 5(6):475-9. PubMed ID: 8195840
[TBL] [Abstract][Full Text] [Related]
27. Dipyrone metabolism in liver disease.
Zylber-Katz E; Caraco Y; Granit L; Levy M
Clin Pharmacol Ther; 1995 Aug; 58(2):198-209. PubMed ID: 7648770
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol.
Lintz W; Barth H; Becker R; Frankus E; Schmidt-Böthelt E
Arzneimittelforschung; 1998 May; 48(5):436-45. PubMed ID: 9638309
[TBL] [Abstract][Full Text] [Related]
30. Famotidine pharmacokinetics following oral and intravenous administration in patients with liver disease: results of a preliminary study.
Morgan MY; Stambuk D
Postgrad Med J; 1986; 62 Suppl 2():29-37. PubMed ID: 2890149
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of cimetidine in patients with liver disease.
González-Martin G; Arancibia A; Fajuri M; Chesta J; Novoa X
Int J Clin Pharmacol Ther Toxicol; 1985 Jul; 23(7):355-8. PubMed ID: 4030163
[TBL] [Abstract][Full Text] [Related]
32. Toxicokinetics of lambda-cyhalothrin in rats.
Anadón A; Martínez M; Martínez MA; Díaz MJ; Martínez-Larrañaga MR
Toxicol Lett; 2006 Aug; 165(1):47-56. PubMed ID: 16513299
[TBL] [Abstract][Full Text] [Related]
33. Picumast dihydrochloride (Auteral), a new anti-allergic inhibitor of mediator release and action.
Wilhelms OH; Roesch A; Schaumann W
Agents Actions Suppl; 1991; 34():335-49. PubMed ID: 1686528
[TBL] [Abstract][Full Text] [Related]
34. Chemical synthesis of picumast dihydrochloride.
Witte EC
Arzneimittelforschung; 1989 Oct; 39(10A):1309. PubMed ID: 2576353
[TBL] [Abstract][Full Text] [Related]
35. Spironolactone metabolism in normal subjects and in patients with liver cirrhosis.
Váradi A; Fehér T; Bodrogi L; Koref O
Arzneimittelforschung; 1977; 27(8):1618-20. PubMed ID: 578759
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of pyrazinamide and its metabolites in patients with hepatic cirrhotic insufficiency.
Lacroix C; Tranvouez JL; Phan Hoang T; Duwoos H; Lafont O
Arzneimittelforschung; 1990 Jan; 40(1):76-9. PubMed ID: 2340003
[TBL] [Abstract][Full Text] [Related]
37. Serum levels and urinary excretion of mequitazine after a single oral dose.
Ylitalo P; Nieminen K; Wilén-Rosenqvist G; Fourtillan JB; Girault J; Ylitalo L; Pukander JS; Karma PH
Int J Clin Pharmacol Res; 1989; 9(5):305-8. PubMed ID: 2576245
[TBL] [Abstract][Full Text] [Related]
38. Disposition of nafcillin in patients with cirrhosis and extrahepatic biliary obstruction.
Marshall JP; Salt WB; Elam RO; Wilkinson GR; Schenker S
Gastroenterology; 1977 Dec; 73(6):1388-92. PubMed ID: 913979
[TBL] [Abstract][Full Text] [Related]
39. [Elimination kinetics of phenprocoumon (Marcumar) in liver cirrhosis and after premedication with phenobarbital].
Heni N; Lehnhardt G; Glogner P
Int J Clin Pharmacol Biopharm; 1976 Jun; 13(4):253-61. PubMed ID: 965132
[TBL] [Abstract][Full Text] [Related]
40. [Pharmacokinetics and tolerability of telenzepine in patients with compensated liver cirrhosis].
Reinicke A; Müller P; Dammann HG; Simon B
Arzneimittelforschung; 1990 Nov; 40(11):1239-41. PubMed ID: 2085337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
